Study Subject ID:

EndTB - Event Validation Document

Extraction date:
Treatment arm:
Randomization date:
Treatment outcome at Week 73:
Open Clinica:
Algorithm:
Conclusion:

Validation page

Week 73 Event Validation Group (EVG) final treatment outcome:	
The last two culture results are negative. These two cultures must be from sputum samples collected on separate visits, the latest between weeks 65 and 73	
The last culture result (from a sputum sample collected between weeks 65 and 73) is negative; and either there is no other post-baseline culture result or the penultimate culture result is positive due to laboratory cross contamination; and bacteriological, radiological and clinical evolution is favorable	
There is no culture result from a sputum sample collected between weeks 65 and 73 or the result of that culture is positive due to laboratory cross contamination; and the most recent culture result is negative; and bacteriological, radiological and clinical evolution is favorable.	
Replacement or addition of one or more investigational drugs in an experimental arm or in the control arm if using the shortened regimen (failure)	
Replacement or addition of two or more investigational drugs in the control arm if using the conventional regimen (failure)	
Initiation of a new MDR-TB treatment regimen after the end of the allocated study regimen and before week 73 (relapse)	
Death from any cause	
At least one of the last two cultures, the latest being from a sputum sample collected between weeks 65 and 73, is positive in the absence of evidence of laboratory cross contamination (failure/relapse)	
The last culture result (from a sputum sample collected between weeks 65 and 73) is negative; AND there is no other post-baseline culture result or the penultimate culture is positive due to laboratory cross contamination; and bacteriological, radiological or clinical evolution is unfavorable (failure/relapse)	
There is no culture result from a sputum sample collected between weeks 65 and 73 or it is positive due to laboratory cross contamination; AND the most recent culture is negative; and bacteriological, radiological or clinical evolution is unfavorable (failure/relapse) or, the most recent culture result is positive in the absence of laboratory contamination	
The outcome is not assessable because there is no culture result from a sputum sample collected between weeks 65 and 73 or it is positive due to laboratory cross contamination; AND there is no other post-baseline culture result or the most recent culture is positive due to laboratory cross contamination; or, the most recent culture is negative and bacteriological, radiological and clinical evolution is not assessable	
Previously classified as unfavorable in the present study, except not assessable at week 39	
Concordant with Site Investigator final treatment outcome?	
Date of EVG W73 final treatment outcome assignment (dd/mmm/yyyy):	
Name of the EVG member:	
Signature of the EVG member:	

NOTE: If treatment outcomes from Open Clinica and from the algorithm are concordants, please enter the following informations in Open Clinica:

- Date of EVG final treatment outcome assignment = date of extraction,
- Name of the EVG member = Algorithm,
- Presence of signature = No

Early treatment discontinuation:

Date of last study drug intake: Reason: Specify other:
Early study discontinuation:
Date of last visit: Reason (if different from above): Specify other:
Death:
Date:
Treatment initiation
Treatment change/New treatment
Culture results
Bacteriological, radiographic and clinical evolution

 $Rapid\ molecular\ test\ for\ FQ\ resistance$

DST results

Rapid molecular test for RIF resistance
Chest X-ray
Weight, height, BMI at screening
ECOG assessment
Weight and temperature
Signs and symptoms (grades)